Gene clues may predict breast cancer drug success
NCT ID NCT02329639
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined whether specific gene variations influence how well metastatic breast cancer patients respond to chemotherapy with or without the drug bevacizumab. Researchers enrolled 307 women from Italy to compare outcomes and analyze genetic interactions. The goal was to understand which patients might benefit most from adding bevacizumab to standard chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda USL 5 of Pisa
Pontedera, Pisa, 56025, Italy
-
Department of Clinical and Experimental Medicine, University of Pisa
Pisa, I Am Not in the U.S. Or Canada, 56125, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a Four-Drug cocktail tame a tough breast cancer?
- Can a new drug outsmart resistant breast cancer?